AAA devices
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of the Talent abdominal aortic aneurysm endovascular stent graft is expected by August 2002, the beginning of the firm's second fiscal quarter, Rasdal says. Medtronic currently is in discussions with the agency, following the completion of U.S. clinical trials. The device is the top-selling thoracic stent graft outside the U.S., Medtronic claims. Because the Talent is made from drawn nitinol wire, it should be more suitable for patients with aortic tortuosity than the firm's AneuRx AAA device, which FDA approved in September 1999, Rasdal suggested. Further back in development is a second-generation device, expected to be approved in the U.S. in the spring of 2004, that will leverage the "best" attributes of both the Talent and the AneuRx, according to Rasdal. The company expects the U.S. AAA market to grow to more than $600 mil. by Medtronic's 2006 fiscal year (beginning May 1), driven by an increased diagnosis of aortic aneurysms and a heightened acceptance of intravascular stent grafts
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.